Colonic perforation after rituximab treatment for posttransplant lymphoproliferative disorder

J Pediatr Gastroenterol Nutr. 2013 Jun;56(6):e41. doi: 10.1097/MPG.0b013e3182519cfc.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / adverse effects*
  • Antibodies, Monoclonal, Murine-Derived / therapeutic use
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / therapeutic use
  • Child, Preschool
  • Colon, Sigmoid / drug effects
  • Colon, Sigmoid / immunology
  • Colon, Sigmoid / pathology
  • Colon, Sigmoid / surgery
  • Female
  • Gastrointestinal Hemorrhage / etiology
  • Granulation Tissue / drug effects
  • Granulation Tissue / pathology
  • Heart Transplantation / adverse effects
  • Humans
  • Hypoplastic Left Heart Syndrome / surgery
  • Immunocompromised Host / drug effects
  • Intestinal Perforation / etiology*
  • Intestinal Perforation / pathology
  • Intestinal Perforation / physiopathology
  • Intestinal Perforation / surgery
  • Lymphoproliferative Disorders / drug therapy*
  • Lymphoproliferative Disorders / immunology
  • Lymphoproliferative Disorders / physiopathology
  • Postoperative Complications / drug therapy*
  • Postoperative Complications / immunology
  • Postoperative Complications / physiopathology
  • Rituximab
  • Sigmoid Diseases / etiology*
  • Sigmoid Diseases / pathology
  • Sigmoid Diseases / physiopathology
  • Sigmoid Diseases / surgery
  • Tumor Lysis Syndrome / etiology
  • Tumor Lysis Syndrome / physiopathology*

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Agents
  • Rituximab